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Background: Small bowel angioectasia is reported as the most common cause of bleeding in patients with obscure
gastrointestinal bleeding. Although the safety and efficacy of endoscopic treatment have been demonstrated, rebleeding
rates are relatively high. To establish therapeutic and follow-up guidelines, we investigated the long-term outcomes and
clinical predictors of rebleeding in patients with small bowel angioectasia.
Methods: A total of 68 patients were retrospectively included in this study. All the patients had undergone CE
examination, and subsequent control of bleeding, where needed, was accomplished by endoscopic argon plasma
coagulation. Based on the follow-up data, the rebleeding rate was compared between patients who had/had not
undergone endoscopic treatment. Multivariate analysis was performed using Cox proportional hazard regression model
to identify the predictors of rebleeding. We defined the OGIB as controlled if there was no further overt bleeding within
6 months and the hemoglobin level had not fallen below 10 g/dl by the time of the final examination.
Results: The overall rebleeding rate over a median follow-up duration of 30.5 months (interquartile range 16.5–47.0)
was 33.8% (23/68 cases). The cumulative risk of rebleeding tended to be lower in the patients who had undergone
endoscopic treatment than in those who had not undergone endoscopic treatment, however, the difference did not
reach statistical significance (P = 0.14). In the majority of patients with rebleeding (18/23, 78.3%), the bleeding was
controlled by the end of the follow-up period. Multiple regression analysis identified presence of multiple lesions (≥3)
(OR 3.82; 95% CI 1.30–11.3, P = 0.02) as the only significant independent predictor of rebleeding.
Conclusion: In most cases, bleeding can be controlled by repeated endoscopic treatment. Careful follow-up is needed
for patients with multiple lesions, presence of which is considered as a significant risk factor for rebleeding.
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Obscure gastrointestinal bleeding (OGIB), defined as per-
sistent or recurrent bleeding with negative findings on
upper and lower gastrointestinal endoscopic evaluations
[1], accounts for about 5% of all cases of gastrointestinal
bleeding [2]. Capsule endoscopy (CE), introduced in 2000,
has become established as the examination modality of
first choice for the investigation of OGIB [3-6] and* Correspondence: endo1978@yokohama-cu.ac.jp
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unless otherwise stated.other small bowel abnormalities [7-10]. The diagnostic
yield of CE has been reported to range from 45% to
80% [6,11-15], as high as that of balloon-assisted entero-
scopy (BAE) [16,17].
Angioectasia is the most commonly occurring vascular
malformation of the gastrointestinal tract [18]. Although
small bowel angioectasia was previously considered to
be rare, with recent advances in endoscopic modalities
(e.g. CE and BAE), this condition is being detected
increasing frequently in clinical practice. Recent studies
have revealed that small bowel angioectasia is the most
common cause of bleeding, sometimes life-threatening,
in patients with OGIB [19,20]. Although several studiesd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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treatment for small bowel angioectasia [21,22], not all
patients with OGIB can receive endoscopic treatment,
because the procedure is complex and time-consuming.
Moreover, relatively high rebleeding rates have been
reported in patients with small bowel angioectasia [23-26]
and the predictors of rebleeding have not yet been fully
clarified. Therefore, there is a need for therapeutic and
follow-up guidelines to be established.
We conducted the present study in a relatively large
cohort to determine the efficacy of endoscopic treatment
and the long-term outcomes in patients with small
bowel angioectasia. In addition, the clinical predictors of




This cohort study was conducted to reveal the long-term
outcomes in patients with small bowel angioectasia. Of
386 consecutive patients with OGIB who underwent
CE at Yokohama City University Hospital or any of four
tertiary hospitals (Yokohama Rosai Hospital, Chigasaki
Municipal Hospital, Odawara Municipal Hospital and
Hiratsuka City Hospital) between October 2007 and
October 2012, we enrolled 74 patients who were detected
to have at least one small bowel angioectasia. All of the
patients had undergone upper and lower endoscopic
examinations prior to the CE, with negative findings. To
investigate the long-term outcomes of patients with small
bowel angioectasia, and the risk factors for rebleeding
in these patients, patients with other definitive lesions
(e.g. ulcers, Dieulafoy’s lesions, varices, anteriovenous
malformations, diverticula or tumors) were excluded.
In addition, patients with failed CE examination due to
CE retention, incomplete small bowel transit or poor
bowel preparation were also excluded. The study protocol
was approved by the Ethics Committee of Yokohama
City University Hospital, Odawara Municipal Hospital,
Chigasaki Municipal Hospital, Yokohama Rosai Hospital
and Hiratsuka City Hospital. Written informed consent
was obtained from all of the subjects prior to their partici-
pation in the study.
Clinical information
We registered the patient data from the database, includ-
ing the type of OGIB, the age and sex of the patients,
smoking history, alcohol history, blood transfusion history,
minimum hemoglobin concentration, presence/absence
of comorbidities, and the current medication history at
the time of the initial CE. According to the bleeding
pattern, the OGIB was classified into two categories; overt,
manifesting as melena or hematochezia, and occult, mani-
festing as recurrent IDA and/or a positive fecal occult bloodtest without any visible bleeding. In addition to the infor-
mation from the database, follow-up data, including the
data at the final examination, change in the hemoglobin
level, presence/absence of overt bleeding, and the treat-
ment history were obtained retrospectively from the
hospital medical records or the responses to questionnaires
collected by the doctors of other hospitals/clinics. The
follow-up duration was defined as the time from the first
CE examination to the last medical examination.
Capsule endoscopy
The patients were instructed to swallow the CE capsule
(PillCam SB or SB2; Given Imaging, Yoqneam, Israel)
with a solution of dimethicone after fasting overnight,
with no other bowel preparation. They were allowed to
drink clear liquids 2 hours after they had swallowed the
capsule, and a light meal 4 hours after. Two CE experts
(with experience of reporting more than 150 CE videos)
separately read and interpreted the complete CE videos.
When there were discrepancies in the interpretation,
both the experts reviewed the findings simultaneously
and reached a consensus.
Definition of small bowel angioectasia
Angioectasia is a venous lesion that requires cauterization;
Dieulafoy's lesions and arteriovenous malformations may
cause arterial bleeding, and require clipping or surgical
treatment. According to a previous report [27], angioectasia
is a punctate (<1 mm) or patchy (a few mm) erythematous
lesion (Figure 1) with or without oozing, that is diagnosed
by CE and/or BAE, as histologic confirmation cannot be
obtained for most of these lesions. In the present study,
both punctate and patchy erythema were considered as
definitive diagnostic findings, and the locations and sizes of
the angioectasia were recorded according to the results of
the CE examination. Each of the CE videos was divided
into two segments of equal length according to the small-
bowel transit time; the first segment was considered as
representing the proximal small bowel and the second as
representing the distal small bowel.
Treatment of small bowel angioectasia
In this study, all the patients had undergone CE examin-
ation prior to any endoscopic treatment. Subsequent
endoscopic treatment was undertaken when active bleeding
was identified by CE. In addition, endoscopic treatment
was also undertaken for patients with ongoing overt bleed-
ing (within three days) and/or drop of the hemoglobin level
by more than 2 g/dl within two weeks after the first episode
of OGIB. If endoscopic treatment was needed to control
small bowel bleeding, single-balloon enteroscopy (SBE)
(SIF-Q260, Olympus Optical, Tokyo, Japan) was performed
within 5 days of the initial CE examination. The insertion
route was determined by the location of the lesions
Figure 1 Capsule endoscopic findings of small bowel angioectasia. A: punctate angioectasia (arrow). B: patchy angioectasia (arrowhead).
Figure 2 Study flow diagram. *Patients with other definitive small
bowel lesions, such as ulcers, Dieulafoy’s lesions, varices, anteriovenous
malformations, diverticula and tumors, were excluded.
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be identified by one route, another route was used. For
cases where a bleeding source was clearly detected
during the procedures, total enteroscopy was not always
attempted. For angioectasias, endoscopic argon plasma
coagulation (APC) was performed at an output of 40 W
and an argon gas flow rate of 1.6 L/min. Basically, an
attempt was made to treat all the angioectasias detected
by the SBE, although some non-bleeding small angioecta-
sias were left untreated if there were too many lesions to
treat. No serious complications were encountered in any
of the patients during the study.
Definition of the rebleeding and control rate
The main outcome variable of this study was the inci-
dence of recurrent bleeding. Rebleeding was defined as
evidence of recurrent visible gastrointestinal bleeding
(hematochezia or melena) with recent negative upper
and lower endoscopic examinations and/or a reccurent
drop of the hemoglobin level by more than 2 g/dl from
the baseline. We defined the OGIB as controlled when
there was no further overt bleeding within 6 months of
the initial episode and the hemoglobin level did not drop
to below 10 g/dl by the time of the final examination.
Statistical analysis
The statistical significances of differences in the values
of the clinical parameters were evaluated by Fisher’s
exact test and an unpaired student’s t-test. Follow-up
data related to the rebleeding-free interval were analyzed
by the Kaplan-Meier method and log-rank test. Univari-
ate and multivariate analyses were performed using Cox
proportional hazard regression models to identify the
predictors of rebleeding in patients with small bowel
angioectasia. For the multivariate analysis, only variables
identified as being significant with P values of <0.1 by
the univariate analyses were included as covariates.
Unless otherwise specified, P values of <0.05 were con-




Of the 74 patients enrolled in this study, 6 patients who
were followed up for less than 1 year, were lost to
follow-up, or died of other causes were excluded. Finally,
a total of 68 patients were included for the analysis in
this study (Figure 2).
Demographic characteristics and clinical data
The demographic and clinical characteristics of the patients
with small bowel angioectasia are shown in Table 1. Of the
68 patients, 22 (32.4%) received endoscopic treatment,
while 46 (67.6%) were managed conservatively with or
without iron replacement therapy. While 17 patients
who underwent endoscopic treatment (77.3%) required
blood transfusion, only 14 patients who did not undergo
endoscopic treatment (30.4%) needed blood transfusion
Table 1 Demographic and clinical characteristics of the study patients
Characteristics Total Endoscopic treatment (+) Endoscopic treatment (-) P value*
Number 68 22 46
Bleeding pattern (overt/occult) 40/28 19/3 21/25 0.002
Number of angioectasia, mean (median) 3.4 (2.5) 4.0 (2.0) 3.1 (3.0) 0.68
Age, year, mean ± SD 67.6 ± 12.8 66.9 ± 10.9 66.5 ± 13.6 0.30
Sex, Male/Female 38/30 11/11 27/19 0.60
Drinking history (%) 23 (33.8) 11 (50.0) 12 (26.0) 0.06
Smoking history (%) 24 (35.3) 7 (31.8) 17 (37.0) 0.79
Blood transfusion (%) 31 (45.6) 17 (77.3) 14 (30.4) 0.001
Minimum hemoglobin value, g/dl 9.3 ± 2.7 8.0 ± 2.0 9.9 ± 2.9 0.006
Follow-up duration, month, median (IQR) 30.5 (16.5-47.0) 34.0 (21.0-46.5) 30.0 (18.0-46.0) 0.76
Rebleeding rate, number (%) 23 (33.8) 5 (22.7) 18 (39.1) 0.27
Iron replacement therapy after OGIB, number (%) 59 (86.8) 20 (91.0) 39 (84.8) 0.71
Comorbidity, number (%)
Hypertension 46 (67.6) 19 (86.4) 27 (58.7) 0.03
Diabetes 15 (22.1) 7 (31.8) 8 (17.4) 0.22
Cardiovascular disease 18 (26.5) 8 (36.4) 10 (21.7) 0.25
Cerebral infarction 9 (13.2) 3 (13.6) 6 (13.0) >0.99
CKD, ≥ stage 4 17 (86.4) 8 (36.4) 9 (19.6) 0.15
Liver cirrhosis 3 (4.4) 1 (4.5) 2 (4.3) >0.99
Medication used, number (%)
Warfarin 9 (13.2) 4 (18.2) 5 (10.9) 0.46
LDA 27 (39.7) 10 (45.5) 17 (37.0) 0.60
Thienopyridine 9 (13.2) 3 (13.6) 6 (13.0) >0.99
NSAIDs 7 (10.3) 2 (9.1) 5 (10.9) >0.99
H2-blockers 17 (25.0) 5 (22.7) 12 (26.1) >0.99
PPIs 25 (36.8) 8 (36.4) 17 (37.0) >0.99
Rebamipide 10 (14.7) 4 (18.2) 6 (13.0) >0.99
Abbreviations: IQR, interquartile range; CKD, chronic kidney disease; LDA, low-dose aspirin; NSAIDs, nonsteroidal anti-inflammatory drugs; H2-blockers, histamine H2
receptor antagonists; PPIs, proton pump inhibitors.
Variable definitions: Alcohol history was defined as positive if the subject’s alcohol consumption exceeded 20 g/day. Smoking history was defined as positive if the
subject had smoked more than 10-pack years and was still smoking or had quit within the previous 10 years. History of antiplatelet drug and/or NSAID use was
defined as positive if the patient had been taking at least 1 pill per day of either of these drugs for more than 1 week within 1 month prior to the CE. History of
anticoagulant drug use was defined as positive if the patient had been taking at least 1 pill of anticoagulant drug per day within one week prior to the CE.
*Differences between endoscopic treatment (+) and (-) were calculated by Fisher's exact test or unpaired student t-test.
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who had undergone endoscopic treatment was significantly
lower than that in the patients who had not undergone
endoscopic treatment (8.0 ± 2.0 vs. 9.9 ± 2.9, P = 0.006).
There was no significant difference in the prevalence of
comorbidities, except for that of hypertension (86.4% vs.
58.7%, P = 0.03), or the rate of medication use between the
patients who had/had not undergone endoscopic treatment.
Association between the rebleeding rate and endoscopic
treatment
The overall rebleeding rate over a median follow-up dur-
ation of 30.5 months was 33.8% (23/68 cases) (interquartilerange 16.5–47.0). In most cases, the first rebleeding episode
occurred within 24 months after the CE, with a median
time to rebleeding of 9.0 months (range 3.0–28.0).
Although the rebleeding rate in the patients who had
undergone endoscopic treatment was slightly lower than
that in the patients who had not undergone endoscopic
treatment, the difference did not reach statistical signifi-
cance (22.7% vs. 39.1%, P = 0.27). As shown in Figure 3,
the cumulative risk of rebleeding tended to be lower in
the patients who had undergone endoscopic treatment
than in those who had not undergone endoscopic treat-
ment, however, this difference also did not reach statistical
significance (P = 0.14).
Figure 3 Cumulative rebleeding rates according to the therapeutic
choice. The risk of rebleeding tended to be lower in the patients who
had undergone endoscopic treatment than in those who had not
received endoscopic treatment, although the difference did not reach
statistical significance (P = 0.14, log rank test).
Table 3 Location of small bowel angioectasias
Proximal Distal
Total number 153 86
Prevalence, number (%) 54 (79.4) 43 (63.2)
Endoscopic treatment, number (%) 19 (35.2) 10 (23.2)
Rebleeding, number (%) 21 (38.9) 18 (41.8)
NOTE: Each of the CE videos was divided into two segments of equal length
according to the small-bowel transit time. The first segment was considered as
representing the proximal small bowel and the second as representing the
distal small bowel.
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The clinical outcomes after rebleeding in the patients
with small bowel angioectasia are shown in Table 2. Of
the 23 patients who developed rebleeding, the bleeding
was overt (hematochezia or melena) in 12 (52.2%) and
occult (drop of hemoglobin by more than 2 g/dl) in 11
(47.8%) patients. Eight of the 23 (34.8%) patients received
additional endoscopic treatment. In the majority of the
patients with rebleeding (18/23, 78.3%), the hemoglobin
level increased significantly by the end of the follow-up
period (9.1 ± 2.4 g/dl to 11.4 ± 2.1 g/dl, P <0.001).
Location of the small bowel angioectasia
A total of 239 small bowel angioectasias were identified
in this study (Table 3). The lesions were multiple in
83.8% (57/68 cases) of the patients, and were present in
both the proximal and the distal bowel in 42.6% (29/68
cases). The angioectasias occurred more frequently inTable 2 Clinical outcomes after rebleeding in patients




Bleeding pattern (overt/occult) 12/11
Blood transfusion, number (%) 11 (47.8)
Minimum hemoglobin value after rebleeding, g/dl 9.1 ± 2.4
Endoscopic treatment, number (%) 8 (34.8)
Controlled by the end of the follow-up
period*, number (%)
18 (78.3)
Iron replacement therapy after rebleeding, number (%) 23 (100)
Hemoglobin value at the end of the
follow-up period, g/dl
11.4 ± 2.1
*We defined OGIB as controlled if there was no further overt bleeding within
6 months and the hemoglobin level did not drop below 10 g/dl by the time of
the final examination.the proximal small bowel than in the distal small bowel
(64.0% vs. 36.0%). Therefore, antegrade SBE was performed
more frequently to treat the small bowel angioectasia
(35.2% vs. 23.2%).
Factors predicting rebleeding in patients with small
bowel angioectasia
The selected variables and results are shown in Table 4.
Univariate Cox proportional hazard regression analysis
conducted in patients with small bowel angioectasia identi-
fied a past history of blood transfusion (odds ratio [OR]
3.16; 95% confidence interval [CI] 1.30–7.69, P = 0.01),
presence of multiple lesions (≥3) (OR 4.31; 95% CI 1.60–
11.6, P = 0.004), chronic kidney disease (CKD) ≥ stage 4
(OR 2.94; 95% CI 1.29–6.71, P = 0.01) and a history of
warfarin use (OR 3.30; 95% CI 1.29–8.40, P = 0.01) as sig-
nificant factors predictive of rebleeding. Multivariate Cox
proportional hazards regression analysis identified only
presence of multiple lesions (≥3) (OR 3.82; 95% CI
1.30–11.3, P = 0.02) as an independent significant fac-
tor predictive of rebleeding.
Discussion
Herein, we have presented the results of a relatively large,
long-term, cohort study on bleeding from small bowel
angioectasia. Our aim was to evaluate the significance of
endoscopic treatment and determine the long-term out-
comes in patients with small bowel angioectasia. It is
worthy of note that in contrast to the case in previous
studies [23-26], we excluded patients with other vascular
lesions such as Dieulafoy’s lesions, varices and anteriove-
nous malformations from the analyses, so as to obtain
important information on the optimal management of
bleeding from small bowel angioectasia.
There are several reports of studies carried out to
evaluate the outcomes of patients with OGIB after the
initial episode of bleeding. According to these reports,
the long-term rebleeding rates ranged widely from 17%
to 40% [23-26,28-31]. This could be explained by the
heterogeneity in the study population and differences in
the duration of follow-up, management strategies and
definition of rebleeding among studies. Importantly, the
reported rebleeding rates associated with vascular lesions
Table 4 Predictors of rebleeding in patients with small bowel angioectasia
Variables Rebleeding
Univariate (OR 95% CI) P value Multivariate (OR 95% CI) P value
Age >65 years 1.38 (0.54-3.52) 0.50
Male sex 2.11 (0.87-5.15) 0.10 2.52 (0.95-6.70) 0.07
Overt bleeding 2.00 (0.79-5.08) 0.14
Blood transfusion 3.16 (1.30-7.69) 0.01 1.08 (0.32-3.63) 0.91
Minimum hemoglobin value <8 g/dl 2.03 (0.89-4.60) 0.09 2.43 (0.95-6.19) 0.06
Size of angioectasia ≥1 mm 0.80 (0.36-1.75) 0.57
Number of angioectasias ≥3 4.31 (1.60-11.6) 0.004 3.82 (1.30-11.3) 0.02
Drinking history 1.72 (0.75-3.95) 0.20
Smoking history 1.71 (0.75-3.87) 0.20
Comorbidity
Hypertension 1.63 (0.64-4.17) 0.30
Diabetes 0.95 (0.35-2.55) 0.92
Cardiovascular disease 1.89 (0.80-4.48) 0.15
Cerebral infarction 1.68 (0.57-4.95) 0.35
CKD stage ≥4 2.94 (1.29-6.71) 0.01 1.72 (0.58-5.06) 0.33
Liver cirrhosis 3.77 (0.87-16.3) 0.08 3.44 (0.60-19.8) 0.17
Medication use
Warfarin 3.30 (1.29-8.40) 0.01 2.48 (0.79-7.79) 0.12
LDA 1.00 (0.43-2.31) >0.99
Thienopyridine 1.99 (0.74-5.38) 0.17
NSAIDs 1.32 (0.39-4.46) 0.65
H2-blockers 0.75 (0.28-2.01) 0.56
PPIs 1.45 (0.64-3.32) 0.38
Rebamipide 1.17 (0.40-3.45) 0.77
NOTE: For the multivariate Cox proportional hazard regression analysis, only the variables that were identified by univariate analysis as being significant with a
P value of <0.1 were included as covariates.
Abbreviations: OR, odds ratio; CI, confidence interval; CKD, chronic kidney disease; LDA, low-dose aspirin; NSAIDs, nonsteroidal anti-inflammatory drugs;
H2-blockers, histamine H2 receptor antagonists; PPIs, proton pump inhibitors.
Variable definitions: Alcohol history was defined as positive if the subject’s alcohol consumption exceeded 20 g/day. Smoking history was defined as positive if the
subject had smoked more than 10-pack years and was still smoking or had quit within the previous 10 years. History of antiplatelet drug and/or NSAID use was
defined as positive if the patient had been taking at least 1 pill per day of either of these drugs for more than 1 week within 1 month prior to the CE. History of
anticoagulant drug use was defined as positive if the patient had been taking at least 1 pill of anticoagulant drug per day within one week prior to the CE.
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as erosions/ulcers and tumors [23-26]. Consistent with
previous reports, we confirmed a relatively high rebleeding
rate (33.8%) in patients with small bowel angioectasia.
Our results indicated that initial endoscopic treatment
was not sufficient to control the risk of rebleeding from
small bowel angioectasia. This might be attributable to
the following reasons. Firstly, in some patients, even if
the lesions thought to be responsible for the bleeding
are treated appropriately, other tiny lesions can bleed
later. In this study, only 5 patients (including 4 with
bleeding from proximal angioectasia and 1 with bleeding
from distal angioectasia) were identified as having ongoing
active bleeding by CE examination. Most angioectasias
are reported to be non-incidental lesions [32]. Thus it
is difficult to identify which the angioectasia is the sourceof the bleeding. Consistent with a previous report [32],
multiple lesions were observed at a high frequency in this
study (83.8%), and 42.6% of the patients had angioectasias
both in the proximal and in the distal small bowel. There-
fore, all of the lesions, especially some of the tiny lesions,
could not be treated in a single endoscopic treatment
session, even though an attempt was made to treat all
the definitive lesions. In the present study, the size of
the angioectasia was not found to be a factor associated
with rebleeding. Moreover, Shiozaki et al. reported that
tiny lesions rather than larger lesions bled more frequently
[25]. These results suggest that aggressive endoscopic
treatment of tiny lesions is important to prevent future
rebleeding. In addition, careful follow-up is required when
only tiny lesions are detected as the bleeding source.
Secondly, definitive lesions could be overlooked by the
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et al. reported that some angioectasias could be diagnosed
only later even after combined CE and double-balloon
enteroscopy (DBE) examination [33]. Small bowel angio-
ectasia is reported to occur more frequently in the
proximal small bowel than in the distal small bowel
[23,34]. Because of rapid capsule transit or reduced
bowel visibility due to the presence of bile and bubble
artifacts [35], small bowel lesions, especially those located
in the proximal small bowel, are likely to be overlooked by
CE. Recently, improved visibility and detectability of small
bowel angioectasia has been reported with the use of
computed virtual chromoendoscopy systems, such as
flexible spectral imaging color enhancement (FICE) [36,37].
Additional studies are needed to evaluate whether the use
of such image-enhancing modalities could contribute to
reducing the risk of rebleeding from small bowel angioec-
tasia. Finally, the lower diagnostic yield of SBE could have
affected the outcomes of the patients enrolled in this
study. SBE was subsequently introduced to avoid the
time-consuming and complex DBE procedure. Although
SBE and DBE appear to be equivalent in terms of the
therapeutic outcomes and re-bleeding rates for small
bowel lesions [38,39], decreased rates of total enteroscopy
was observed in cases examined by SBE.
Consistent with a previous report [25], presence of
multiple lesions was identified in this study as a significant
risk factor for the occurrence of rebleeding. In the present
study, while the first rebleeding episode occurred after
1 year in approximately 50% of the cases, in the majority
of cases, rebleeding occurred within 2 years, suggesting
that patients with small bowel angioectasia, especially
those with multiple lesions, should be closely followed up
for at least 2 years after the initial treatment. Although
our results suggested that rebleeding could be controlled
by repeat endoscopic treatment and iron replacement
therapy in the majority of patients with small bowel
angioectasia, some patients may be unsuitable for endo-
scopic treatment, as angioectasia is frequently detected in
patients older than 60 years of age [32] and is often
accompanied by severe comorbidities such as chronic renal
failure [40] and cardiac valvular disease [41]. Pharmaco-
logical treatments such as thalidomide and octoreotide
might serve as attractive options for these patients [42,43].
Use of anticoagulant therapy was not identified as an
independent significant predictor of rebleeding. In this
study, only 9 patients were receiving anticoagulant therapy,
therefore, the small sample size could have affected the
results of this study.
The present study had some limitations. Firstly, it
was a retrospective study, therefore, a selection bias was
inevitable. Secondly, the number of patients enrolled in
this study was not sufficiently large, which could have
limited our conclusions. Thirdly, not all patients underwentsubsequent BAE for confirmation of the results of CE.
Finally, the choice of treatment and follow-up procedures
were not selected based on a randomized controlled trial
protocol. To establish medical management of bleeding
from small bowel angioectasia, a large prospective ran-
domized controlled trial is needed.
Conclusions
Our results indicate that OGIB patients with small bowel
angioectasia show relatively high rebleeding rates. Although
a single session of endoscopic treatment was not sufficient
to prevent rebleeding in the future, in most cases, rebleed-
ing could be controlled with repeat endoscopic treatment
and/or iron replacement therapy. Careful follow-up is
needed for patients with multiple lesions, presence of which
was identified as a significant risk factor for rebleeding.
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